This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
A 2017 survey of NHS trusts in England found that only 11% (5/47) had a dedicated AFS programme, while almost all (98%) had an antibacterial stewardship programme.1,2
There is currently no national consensus on an AFS strategy in the UK or Ireland. This leaves hospitals and Trusts to follow local guidance for managing invasive fungal infections, which can be highly variable.3 While different hospitals, Trusts, and regions have employed their own strategies,3 success stories are emerging that show that AFS can be effective at achieving optimal outcomes at a significantly reduced cost.
AFS programme focused on optimising antifungal stewardship: an evaluation of antifungal use in intensive care
Line-related (intravascular catheter-related bloodstream infection)
July 2017–June 2018 (n=43/52): 82.7%
July 2018–June 2019 (n=44/49): 89.7%
July 2019–March 2020 (n=32/35): 91.4%
Culture proven invasive candidiasis was confirmed in >50% of cases (n=136). In 16.9% cases (n=23/136), a change in antifungal therapy was made based on testing results (culture proven)
This patient case study is just one example of how an AFS programme can make a real impact for your patients, and even inform recommendations for future practices.
The future is in our hands. It’s time to shape it. AFS is a necessary and achievable strategy for the management of invasive fungal infections – at its core, AFS programmes seek to optimise the use of diagnostics, protect patients from unnecessary or inappropriate treatments and mitigate future antifungal resistance.3
a. This content provides an overview of different AFS programmes implemented in the UK, based on published data. This is not meant to be a comparative analysis, and the way the information is presented may differ between programmes.
ABS, antibacterial stewardship; AFS, antifungal stewardship; AMS, antimicrobial stewardship; ICU, intensive care unit; MDT, multidisciplinary team; NHS, National Health Service.
Click here for CRESEMBA® (isavuconazole) prescribing information
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021